Web of Science: 6 cites, Scopus: 7 cites, Google Scholar: cites,
Effectiveness of a pharmacogenetic tool at improving treatment efficacy in major depressive disorder : A meta-analysis of three clinical studies
Vilches, S. (AB-Biotics S.A)
Tuson, Miquel (AB-Biotics S.A)
Vieta, Eduard (Centro de Investigación Biomédica en Red de Salud Mental)
Álvarez, E. (Institut d'Investigació Biomèdica Sant Pau)
Espadaler Mazo, Jordi (AB-Biotics S.A)
Universitat Autònoma de Barcelona

Data: 2019
Resum: Several pharmacogenetic tests to support drug selection in psychiatric patients have recently become available. The current meta-analysis aimed to assess the clinical utility of a commercial pharmacogenetic based tool for psychiatry (Neuropharmagen®) in the treatment management of depressive patients. Random-effects meta-analysis of clinical studies that had examined the effect of this tool on the improvement of depressive patients was performed. Effects were summarized as standardized differences between treatment groups. A total of 450 eligible subjects from three clinical studies were examined. The random effects model estimated a statistically significant effect size for the pharmacogenetic guided prescription (d = 0. 34, 95% CI = 0. 11-0. 56, p-value = 0. 004), which corresponded to approximately a 1. 8 fold increase in the odds of clinical response for pharmacogenetic guided vs. unguided drug selection. After exclusion of patients with mild depression, the pooled estimated effect size increased to 0. 42 (95% CI = 0. 19-0. 65, p value = 0. 004, n = 287), corresponding to an OR = 2. 14 (95% CI = 1. 40-3. 27). These results support the clinical utility of this pharmacogenetic based tool in the improvement of health outcomes in patients with depression, especially those with moderate-severe depression. Additional pragmatic RCTs are warranted to consolidate these findings in other patient populations.
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: Article ; recerca ; Versió publicada
Publicat a: Pharmaceutics, Vol. 11 Núm. 9 (september 2019) , p. 453, ISSN 1999-4923

DOI: 10.3390/pharmaceutics11090453
DOI: 10.1071/AN17752
PMID: 31480800


15 p, 1.0 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació Biomèdica Sant Pau
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2020-06-03, darrera modificació el 2022-04-04



   Favorit i Compartir